Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

1.39
+0.01000.72%
Post-market: 1.37-0.0200-1.44%19:59 EST
Volume:3.42M
Turnover:4.70M
Market Cap:368.86M
PE:-17.37
High:1.40
Open:1.36
Low:1.33
Close:1.38
52wk High:4.08
52wk Low:1.30
Shares:265.37M
Float Shares:259.80M
Volume Ratio:1.16
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0800
EPS(LYR):-0.3290
ROE:-553.45%
ROA:4.80%
PB:8.87
PE(LYR):-4.22

Loading ...

Akebia Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 06

Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 06

Akebia price target lowered to $4 from $6 at Piper Sandler

TIPRANKS
·
Feb 06

Akebia Therapeutics Files Initial Beneficial Ownership Statement for Carolyn M. Rucci, SVP and Chief Legal Officer

Reuters
·
Feb 04

BRIEF-Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 03

Akebia Therapeutics Updates Executive Severance and Leadership Terms

TIPRANKS
·
Jan 30

Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline

TIPRANKS
·
Jan 12

BRIEF-Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027

Reuters
·
Jan 12

Akebia Therapeutics Reports Strong Vafseo Growth and Advances Rare Kidney Disease Pipeline

Reuters
·
Jan 12

Akebia Therapeutics Doses First Patient in Mid-Stage Study of Kidney Disease Drug Praliciguat

MT Newswires Live
·
Jan 06

BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat

Reuters
·
Jan 06

Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS

Reuters
·
Jan 06

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

GlobeNewswire
·
Jan 06

Akebia Therapeutics Grants Stock Options to New Employee at $1.61 Per Share

Reuters
·
Jan 06

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 06

Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 02, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 02, 2025

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Benzinga_recent_news
·
Dec 01, 2025